Previous close | 3.8000 |
Open | 4.5000 |
Bid | 4.4000 |
Ask | 5.1000 |
Strike | 310.00 |
Expiry date | 2024-12-20 |
Day's range | 4.5000 - 4.5000 |
Contract range | N/A |
Volume | |
Open interest | 2k |
On May 16, 2024, Rainer Blair, President & CEO of Danaher Corp (NYSE:DHR), executed a sale of 9,005 shares of the company.
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq.